Difference between revisions of "Taloporfin (Laserphyrin)"
Jump to navigation
Jump to search
m |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 4: | Line 4: | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
| − | *2013-09-20: | + | *2013-09-20: New additional indication and a new dosage for the treatment of [[:Category:CNS cancers|primary malignant brain tumor]] (only for the case where surgical excision of tumor is performed). |
| − | *2015-05-26: | + | *2015-05-26: New additional indication for the treatment of recurrent [[esophageal cancer]] associated with local persistence after chemoradiotherapy or radiotherapy. |
| + | ==Also known as== | ||
| + | *'''Brand name:''' Laserphyrin | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
Latest revision as of 23:53, 31 July 2023
Photosensitizer
Diseases for which it is used
History of changes in PMDA indication
- 2013-09-20: New additional indication and a new dosage for the treatment of primary malignant brain tumor (only for the case where surgical excision of tumor is performed).
- 2015-05-26: New additional indication for the treatment of recurrent esophageal cancer associated with local persistence after chemoradiotherapy or radiotherapy.
Also known as
- Brand name: Laserphyrin